• 1
    Samama MM, Cohen AT, Darmon JY, Desjardin L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AGG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793800.
  • 2
    Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 8749.
  • 3
    Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 3259.
  • 4
    Kahn S, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in non surgical patients. Chest 2012; 141(2 Suppl): e195S226S.
  • 5
    Gussoni G, Campanini M, Silingardi M, Scannapieco G, Mazzone A, Magni G, Valerio A, Iori I, Ageno W. In hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study. Thromb Haemost 2009; 101: 893901.
  • 6
    Dentali F, Riva N, Gianni M, Malato A, Bozzato S, Bernasconi M, Tuttolomondo B, Romano A, Pinto A, Siragusa S, Ageno W. Prevalence of renal failure and use of thromboembolic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. Thromb Res 2008; 123: 6771.
  • 7
    Monreal M, Falgà C, Valle R, Barba R, Bosco J, Beato JL, Maestre A. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE registry. Am J Med 2006; 119: 10739.
  • 8
    Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008; 19: 13540.
  • 9
    Parikh AM, Spencer FA, Lessard D, Emery C, Baylin A, Linkletter C, Goldberg RJ. Venous thromboembolism in patients with reduced estimated GFR: a population based perspective. Am J Kidney Dis 2011; 58: 74655.
  • 10
    Decousous H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB, Fitzgerald G, Anderson FA; IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139: 6979.
  • 11
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 381S453S.
  • 12
    Turpie AGG, Lensing AWA, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 2009; 20: 11421.
  • 13
    Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, van Lente F. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration ratea. Ann Intern Med 2006; 145: 24754.
  • 14
    Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Inter Med 2007; 146: 27888.
  • 15
    Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction score. J Thromb Haemost 2010; 8: 24507.
  • 16
    Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF. Low molecular weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011; 365: 246372.
  • 17
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 37383.
  • 18
    Delaneye P, Krzesinski JM. Indexing of renal function parameters by body surface area: intelligence or folly? Nephron Clin Pract 2011; 119: c28992.